

EUDAMED user guide CI/PS for Sponsors

Playground v 3.11.0 2025

Table of Contents

1. Introduction 1
2. Getting started – access the CI/PS module 2
3. Register a CI/PS application 4
3.1. How to complete the application
3.1.1. Coordinated assessment information -
applicable to the CI/PS single application –
coordinated assessment 12
3.1.2. CI/PS identification 14
3.1.3. CI/PS contact person
3.1.4. CI/PS Description - part 1
General description 17
Objectives and endpoints
3.1.5. CI/PS Description – part 2
Planned number of subjects
Dates 20
Population21
Scope of the investigational/study device
Coordinating investigator 26
3.1.6. Common documents and statements
3.1.7. Investigational/Study device(s)
Previous investigation/study?
Device information
Investigational/Study device details
Manufacturer of the investigational/study device
and Manufacturer information
3.1.8. Comparator
3.1.9. National information
National clinical investigation/performance study
information
National investigational/study site(s)
National language-specific information
4. Submit an application/notification
5 Search and manage application / notification 58
5.1. Search CI/PS items
5. 1. Search CI/PS items

6. Withdraw an application	62
7. Delete a draft application	66
8. Validation rejected - Edit and submit response to Competent Authority	67
9. Pending additional info – provide additional information	72
10. Submit normal update	73
11. Register start date	76
12. Deadlines applying to the CI/PS application – one country	79
13. Deadlines applying to the PMCF/PMPF notification	80
14. Notifications triggered by the system	81

Playground

1 Introduction

The purpose of this user guide is to help you navigate through the Clinical Investigation and Performance Studies (CI/PS) module in EUDAMED.

This guide assumes the reader is acquainted with the Regulation (EU) 2017/745 on Medical Devices and Regulation (EU) 2017/746 on *in vitro* Diagnostic Medical Devices, hence no specific rules or other guidance will be provided in relation to certain registration steps.¹



¹For a wider understanding on how to use the platform, including FAQs and process infographics, visit the EUDAMED Information Centre.

2 Getting started – access the CI/PS module

Prerequisite to access EUDAMED:

EU Login (ECAS) account

If you do not have an EU Login account, please follow the instructions for creating an account before attempting to use the EUDAMED database.

Click on the following link to arrive to the EUDAMED Playground page

You will be prompted to enter EUDAMED via your EU Login account.

Once logged in, your dashboard will show links to use the CI/PS module.

Useful EUDAMED symbols and features:

• Red asterisk: mandatory field, e.g.:

Full title		
Full title		

• **Closed red padlock**: information that will not be publicly available when the application or notification becomes public, e.g.:



• Clear: to clear the field value:



• **Remove**: to remove a line of the field value, or to remove a sub-section or to remove a document, when additional values, sub-sections or documents were added by the user previously:



• **Check/uncheck all**: to check all or to uncheck all available options for a field where multiple values are accepted:

of subjects
<u>Uncheck all</u>

Playground

3 Register a CI/PS application

VIDEO: Resubmission of the CI/PS application/notification



VIDEO: CI/PS Submission for additional countries

EUDAMED Video support



NOTE The system saves the data you enter automatically. There is no Save button.

Register a CI/PS application

EUDAMED user guide

Home Tasks 🗸 Search & view 🗸 News Help 🗸		Agence federal Sante Logout
	CURRENT ACTOR: Sponsor, IT-SP-000007947, S	Sponsor Organisation - Italy [Italy] * <u>Notifications</u>
Welcome to EUDAMED		
MDR EUDAMED is the IT system developed by the European Commission to implement Regulation (EU) 2017/745 C on medical devices and Regulation (EU) 2017/746 C on in vitro diagnosis medical devices.	Release note 🗮 2024-07-25 Release note!	
MDR EUDAMED is structured around 6 interconnected modules and a public site.		
Tasks		
According to your profile per module, consult, verify and/or manage your own and related data	(managed by your actor)	
User management	UDI-DIs/Device	CI/PS
My Actor data Assess user access requests Manage your users Manage your actor data	Manage your NRDs	Manage CI/PS application and PMCF/PMPF notification Register CI/PS application or PMCF/PMPF notification
Manage your email notifications		

To start, you have two options in the dashboard:

- Click Register CI/PS application or PMCF/PMPF notification
- Click Search and Manage application/notification and click the Create CI/PS Form button at the top right corner.

		CURRENT ACTOR: Sponsor, IT-SP-000000661, Sponsor organisation - Italy [Italy]
Search and Manage	CI/PS items	Create CI/PS Form +
Search		
Search criteria	Value	
Please select		
Add		
Search		

1. Select the form you want to submit from the drop-down list.



Submission for additional country(ies)

Submission for additional country(ies):

2.

- If you select **CI/PS application one country** in the field *Select the template type for the new dossier*, this means that the new application will be submitted only to the country which will be selected in step 7 below.
- If you select **CI/PS single application coordinated assessment**, this means that the new application will be submitted to all countries specified in the dedicated field *Country for this application* in the *Coordinated assessment information* screen.
- If you select **PMCF/PMPF notification**, this means that the new notification will be submitted only to the country which will be selected in step 7 below.

When you create the application for submission to additional country(ies), it will be populated with the information from the latest application (version) that was submitted for that EU SIN. If all the information corresponds with the new submission, you only need to fill in the national information for each new country.

All the fields are editable, except the CI/PS plan code (see support clip CI/PS Submission for additional countries).

Resubmission:

When you create a resubmission, the form will be populated with the information from the original application. You need to adapt the data as appropriate before submitting the new application/notification.

All the fields are editable, except the CI/PS plan code (see support clip CI/PS Resubmission).

3. If you are initiating a first submission in EUDAMED of a CI/PS application – one country or a PMCF/PMPF notification: Reply Yes or No to the question *Does this concern the registration of an application/notification already submitted outside EUDAMED and which is allowed to start or started already?*



4. If you are initiating a submission for additional country(ies):

Reply Yes or No to the question Does this concern the registration of an application/ notification already submitted outside EUDAMED and which is allowed to start or started already?

Reply Yes or No and enter the linked EU SIN reference, by choosing the relevant result from the drop-down list.

CI/PS application - one country	,
[°] Submission type	
Submission for additional country(ies)	
Does this concern the registration of an application/notification already submitted outside EUDAMED and Yes	which is allowed to start or started already
* Does this concern the registration of an application/notification already submitted outside EUDAMED and	which is allowed to start of
Ind	which is allowed to start or started already

5. If you are **resubmitting an application/notification**:

Reply Yes or No to the question *Does this concern a resubmission for which the original submission was rejected/refused/withdrawn outside of EUDAMED?* If you reply *No*, **enter the original application ID** by choosing the relevant result from the drop-down list.

The system will retrieve all the applications/notifications that have been withdrawn by your actor and applications submitted by your actor that have been rejected or refused by the Competent Authority.

Resubmission		
Does this concern a	resubmission for which the original submissio	n was rejected/refused/withdrawn outside of EUDAMED
No		
Enter the original Ap	plication ID	

If you reply Yes to the previous question, reply Yes or No to Does the EU SIN (generated by EUDAMED) exist?

Reply Yes or No to the question Was this resubmission allowed to start before EUDAMED CI/PS was available?

If you replied Yes to the question *Does the EU SIN (generated by EUDAMED) exist?*, you will need to select a value for *Enter the linked EU SIN reference*:

pes the EU SIN (generated by EUDAMED) exist?	
es	~
as this result mission allowed to start before EUDAMED CI/PS was available?	
	~

6. Select the proposed **Actor ID/SRN**.

Sponsor Actor ID/SRN	
	-

7. In the case where this is a first submission or any submission for which no related EU SIN exists, you need to select the **type of investigation/study** from the drop-down list.

1	Type of investigation / study	
	Type of investigation / study	~
	Clinical investigation application (MDR Art. 62(1)) - one country Other clinical investigation application/notification (MDR Art. 82(1) and applicable national leg Performance study application (IVDR Art. 58(1)) - one country	islatior

The above view **depends on the form you are submitting**. For a **PMCF/PMPF notification (first submission)** you will have the following options:

* Type of investigation / study
Type of investigation / study

PMCF investigation notification (MDR Art. 74(1)) PMPF study notification (IVDR Art. 70(1))

For a **CI/PS single application – coordinated assessment (first submission)** you will have the following options:

Type of investigation / study	* Type of investigation / study	
	Type of investigation / study	~
Type of investigation / study	Type of investigation / study	
Clinical investigation application (MDR Art. 62(1)) - multiple countries (coordinated assessment Performance study application (IVDR Art. 58(1)) - multiple countries (coordinated assessment)	Clinical investigation application Performance study application	(MDR Art. 62(1)) - multiple countries (coordinated assessment) (IVDR Art. 58(1)) - multiple countries (coordinated assessment)

8. Select the **country** from the drop-down list. Only EU+ ² countries are available for selection. This step does not apply to the form type *CI/PS single application* – *coordinated assessment* or to the *Resubmission* that exists in EUDAMED.

Country for this application (EEA countries, United Kingdom (Northern Ireland) and Türkiye)	
Country for this application (EEA countries, United Kingdom (Northern Ireland) and Türkiye)	
Austria	
Belgium	
Bulgaria	
Croatia	
Cyprus	
Czechia	
Denmark	
Estonia	
Finland	
France	
Germany	
Greece	
Hungary	
celand	
reland	
taly	
atvia	
Liechtenstein	
Lithuania	



IMPORTANT

If you are **initiating a submission for additional country(ies)**, you cannot submit an application/notification for a country for which an application/notification already exists on the same EU SIN.

9. Click Create Form at the bottom of the screen.

name:	
Contact person - Last name:	Smith
Contact person - Telephone number:	+954788
Contact person - Email:	pat.smith@sponsor.it

Below you can find a table with a summary of the fields that you have to fill in, depending if you are managing a first submission, a resubmission or a submission of additional country(ies):

Submission type	Type of investigation/ study and Applicable legislation	Country for this application	Enter the original Application ID	Enter the linked EU SIN reference
First submission	Yes	Yes ^{a.}		
Resubmission			Yes	
Submission for additional country(ies)		Yes ^{b.}		Yes

^a·Except for CI/PS single application – coordinated assessment.

²EEA, Northern Ireland and Türkiye.

^bExcept for CI/PS single application – coordinated assessment.

3.1 How to complete the application



NOTE

For this guide we are using the CI/PS application - one country form. The other forms available are very similar but we will identify their differences when relevant.

Once you have filled in all the fields as explained in the previous chapter, the system will create a draft record and generate an Application ID, the EU SIN and the National SIN.

The **Application ID** is different for every application or notification and has the following format:

- For CI/PS: CI or PS (identifies if it is a clinical investigation or a performance study). For PMCF/PMPF: CF or PF (identifies if it is a post-market clinical follow up or a post-market performance follow up).
- 2. The country code or 'EU' if it is an application for coordinated assessment
- 3. The year of initiation of the application/notification
- 4. Six-digit number that resets every year. There will be a new series of unique identifiers every year, composed by the year and the six-digit number. This composed identifier is unique in the entire system, it is not repeated per country or per type of investigation/study or per sponsor.
- 5. Application/notification sequence number (in the example CI-BE-2023-022328-1, -1 means that this is the first submission for the given clinical investigation application; in the example CI-AU-2022-000555-2, -2 means that there is a submission for an additional country (Austria) for the same clinical investigation; in the example CF-BE-2023-001119-R2, -R2 means that two resubmissions were done for the same application)

The **EU SIN** is the unique identifier of the investigation/study and will be shared among all resubmissions and submissions for additional country(-ies) that refer to the same first submission. It is built as follows:

The **National SIN**, which is displayed in the National information section, is the same as the EU SIN except for the code 'EU' which is replaced with the relevant country code.

- element 1 above
- EU

• elements 3 and 4 above

At the top of the page you can see the version number of the draft record and the date of the last update.



The first section of the form, named **Report Primary Details**, gives you an overview of the data already entered.

Report Primary Details	
Form Type CI/PS application - one country Submission type First submission	
started already? Yes	ation/notification already submitted outside EUDAMED and which is allowed to start or
Type of investigation / study and Applicable leg Clinical investigation application (MDR Art. 62(1))	gislation - one country
Country for this application (EEA countries, Un Austria	ited Kingdom (Northern Ireland) and Türkiye)
EU SIN (European Single Identification Number CI-EU-2024-000024	r)
Sponsor identification	
Actor ID/SRN:	AU-SP-000000201
Name:	Sponsor NonEU acceptance
Address:	123 Sydney road 1000 Canberra Australia
Telephone number:	1234567
Email:	ff@hh.hh
Contact person - First name:	Non-EU
Contact person - Last name:	Sponsor
Contact person - Telephone number:	
Contact person - Email:	ff@hh.hh



NOTE

If you are **resubmitting an application**, the report primary details will have an extra field: *This is a resubmission of* which displays the original Application ID for which the current form is a resubmission.



Does this concern a resubmission for which the original submission was rejected/refused/withdrawn outside of EUDAMED? Yes

Does the EU SIN (generated by EUDAMED) exist? No

Was this resubmission allowed to start before EUDAMED CI/PS was available?

Type of investigation / study and Applicable legislation Clinical investigation application (MDR Art. 62(1)) - one country

3.1.1 Coordinated assessment information - applicable to the CI/PS single application – coordinated

assessment

Click Coordinated assessment information from the left menu

Select the countries from the drop-down to which the single application will be submitted.



You can only select countries for which the competent authority has declared to be ready to participate in a coordinated assessment procedure.

Coordinated assessment	information	
* Country for this single application for co	ordinated assessment 🧑	
Austria	•	Remove
		Remove
Austria		
Belgium	m (Northern Ireland) and Türkiye	
Bulgaria	t Authority 🔒	
Croatia		
Cyprus		
Czechia		
Denmark		
Estonia		
Finland		
-		

As soon as you select the country, the system will load the national information section specific for the selected country.

To add more countries click Add.





Choose the proposed coordinating *Competent Authority* from the drop-down list. You will see only the Competent Authorities linked to the countries that you have selected above and that are available to be the coordinating Competent Authority.

Proposed coordinating Compe	tent Autho	ority 🔒	
]	
AT-CA-029 - Carlson Company Ltd.			

3.1.2 CI/PS identification

Click CI/PS Identification from the left menu.

In this section you must identify your CI/PS plan by providing the following information:

- CI/PS plan code: This value will no longer be editable in a new version of this application or any linked application (re-submission or submission for additional country/-ies).
- CI/PS plan version
- CI/PS plan date: You can only choose a date in the past.
- Full title
- Short title
- Title for lay people

If you are submitting a pre-existing application/notification, depending on the information you have provided during the registration step, further details will be requested in the section *Information on the pre-existing application/notification*:

Information on the pre-existing application/notification
* Please provide the application/notification identifier(s) and/or the CI/PS identifier(s) (e.g. CIV ID) of the original application/notification that was(were) assigned by the national Competent Authority and that was(were) rejected/refused/withdrawn outside EUDAMED
Add
* Please provide the application/notification identifier(s) and/or the CI/PS identifier(s) (e.g. CIV ID) that was(were) assigned by the national
Competent Authority outside EUDAMED for the current application/notification
Add
*What is the status of the CI/PS application or PMCF/PMPF notification?
Please select

Once the CA accepts the pre-existing application/notification, the state will correspond to the value that is selected in this field.

If you choose *Ended*, *Terminated early* or *Temporarily halted* the system will display two new fields, asking you to indicate the start date and the end/termination/halt date.

Ended	•	Clear
What was the start date?		
What was the end/termination/halt date?		

3.1.3 CI/PS contact person

1. Click CI/PS contact person from the left menu.

If your organisation is not establis Ireland only) or Türkiye, you will be the contact person of the Sponsor's	hed in the EEA, United Kingdom (No asked to provide a legal representati legal representative.
Sponsor's legal representative ident	fication
 Sponsor's legal representative identification 	
*Organisation name	*Street
*Street number	'Postal code
*City name	Country 😧
*Telephone number	*Email
Contact person of the sponsor's lega	I representative
 Contact person of the sponsor's legal representative First name 	Last name 🔒

- 2. Choose the *contact person* of the CI/PS from the drop-down list:
 - Same as contact person of Sponsor
 - Same as contact person of Sponsor's legal representative: this option will appear only if you have a legal representative.
 - **Other**: if you select this option, you will be asked to provide the details of the contact person.

ontact person for the CI/PS	
ontact person is A	
Same as contact person of sponsor	
Same as contact person of sponsor's legal represent	ative

3. If you select *Same as contact person of Sponsor* the below message will be displayed:

3.1.4 CI/PS Description - part 1

Select CI/PS description - part 1 from the left menu.

General description

1. Reply to the question *Has the manufacturer obtained the views of the expert panel* on the clinical investigation according to Art 61(2) of Regulation (EU) 2017/745? by selecting Yes or No from the drop-down list.

General	description
* Has the man 2017/745?	ufacturer obtained the views of the expert panel on the clinical investigation according to Art 61(2) of Regulation (EU)
Yes	ed the views of the expert panel on the clinical investigation according to Art 61(2) of Regulation (EU) 2017/745? is a mandatory field duct (worldwide)
No	- Clear

2. Add more countries of conduct, if relevant.

Afghanistan	
Albania	
Algeria	
American Samoa	
Andorra	
Angola	
Anguilla	
Antarctica	
Antigua and Barbuda	
Controlled	

3. You can **add several countries**. To do it click **Add** and select the country from the drop-down list.

Additional countries of conduct (worldwide)		
Brazil	•	Clear
Add		

4. Select the **type of design**. At least one option must be selected.

Type of design
Exploratory investigation
Confirmatory investigation
Observational investigation

5. Reply Yes or No to the question First in human?

First in huma	n?	
Yes	ory field	
No	y indatory field	

6. Select the *design methodology*. At least one option must be selected.

* Design met Design methodo <u>Check all</u> <u>U</u>	thodology logy is a mandatory field Incheck all		
Case cont	trol		
	t		
Cross-sec	ctional		
Double bli	ind		
Single blir	nd		
Randomis	sed		
Open			
Other			

7. If you select the option *Other* you will be required to provide further information. Select the **development stage** from the drop-down list. You can select only one option.

Pilot stage	ory field	
Pivotal stage	l endpoints	
Post-market stage		

Objectives and endpoints

Provide the following information:

- Primary
- · Secondary objective
- Other objective(s)
- Primary endpoint
- · Secondary endpoint
- Other endpoint(s)
- · Overall synopsis

3.1.5 CI/PS Description – part 2

Click CI/PS Description – part 2 from the left menu.

Planned number of subjects

Insert the planned number of subjects in:

- Europe
- Asia
- Africa
- North America
- South America
- Oceania

At the end, you can indicate the total number of subjects.

Dates

In this field, indicate the estimated start and end dates of the CI/PS, when relevant.

To select the date click on the calendar icon.

Dates	
* Estimated start date	
* Estimated end date	

Alternatively, you can insert the date in the format YYYY-MM-DD.



The start date cannot be in the past.



IMPORTANT

If you are submitting a **PMCF/PMPF notification** (first version), you have to select an *Estimated start date* which is at least 30 calendar days from the date of submission.

If you are submitting a pre-existing application/notification and in the *CI/PS identification* section you selected the value *Not yet started*, either only the *Estimated end date* will appear or none of the date fields.

Population

1. Reply Yes or No to the question Is there an associated medical condition?

Populatio	n	
* Is there an ass	sociated medical condition?	1
Yes	al condition? is a mandatory field	
No	• ()	

- 2. **If you reply Yes**, the question *Is the medical condition considered to be rare*? will appear for you to reply.
- 3. For MDR Select the **therapeutic area** by clicking **+ Therapeutic area**.



4. A new section will appear for you to choose the medical and therapeutic areas.

The	rapeutic area *	
- I	herapeutic area	
	* Medical area 😮	
	Please select	•
	* Therapeutic area	
	Please select	•

- 5. The medical area you choose will determine the options you will have under the therapeutic drop-down list.
- 6. You can **add more therapeutic areas** by clicking **Add**.

erapeutic area	
* Medical area 😮	
Obstetrics & gynaecology including reprod	luctive medicine - Clear
* Thoropoutio area	
* Therapeutic area	- Clear
* Therapeutic area Devices for obstetrics and gynaecology	✓ Clear
* Therapeutic area Devices for obstetrics and gynaecology	✓ Clear

NOTE In case of Performance Studies (IVDR) the section Diagnostic area will show instead of Therapeutic area. A new field will appear to select the Diagnostic area.
Diagnostic area *
+ Diagnostic area
Add
The Diagnostic area codes are the EMDN nomenclature codes for IVD devices.

The Diagnostic area codes are the EMDN nomenclature codes for IVD devices. The values are restricted to the EMDN codes starting with "W" (In vitro diagnostic medical devices) at level 3 or 4 of the nomenclature structure. See the European Medical Device Nomenclature (EMDN) for more information.

Diagnostic area	*	
- <u>Diagnostic area</u>		
* Diagnostic area (E	MDN code)	
Please select		•
Diagnostic area des	cription	
		11
Add		
Add	I retrieve the description, ente	r "W" and at least the fi

Diagnostic area (EMDN code)	
N02020	
W02020199: Cell counting instruments - other	
W02020399: Blood grouping instruments - other	
W02020499: Flow cytometry instruments - other	
W02020501: Histological samples analysers	

The system will display the relevant options to select from.

You can add several Diagnostic area codes by clicking Add.

7. Provide the **sex of the subjects**.

* Sex of subjects
Sex of subjects is a mandatory field
Female
Male
Other

- 8. Indicate the inclusion and exclusion criteria.
- 9. Choose the **type of subjects**.



10. Choose the **age range**.

* Age range

Age range is a mandatory field

- In utero
- Preterm Newborn Infants (up to gestational age < 37 weeks)</p>
- Newborns (0 27 days)
- Infants and toddlers (28 days 23 months)
- Children (2 11 years)
- Adolescents (12 17 years)
- Adults (18 64 years)
- □ Elderly (>= 65 years)

Scope of the investigational/study device

1. Choose the device purposes:

* Device purposes
Check all Uncheck all
Diagnosis of disease
Prevention of disease
Monitoring of disease
Prediction of disease
Prognosis of disease
Treatment of disease
Alleviation of disease
Diagnosis of an injury or disability
Monitoring of an injury or disability
Treatment of an injury or disability
Alleviation of an injury or disability
Compensation for an injury or disability
Investigation of the anatomy or of a physiological or pathological process or state
Replacement or modification of the anatomy or of a physiological or pathological process or state
D Providing information by means of in vitro examination of specimens derived from the human body, including organ, blood and tissue donations
Devices for the control or support of conception
Products specially intended for the cleaning, disinfection or sterilisation of devices
No medical purpose, but device belongs to a group of devices listed in MDR Annex XVI

- Reply Yes or No to the question Is this a combined investigation/study testing two different products (i.e. an MD and an IVD, which in combination reach an intended purpose) and/or is it an investigation/study testing a combined product (MD + IVD)?
- If you reply Yes, a new section will appear, from where you can select the form type you want to link to the application/notification. Then choose from the drop-down list the EU SIN of the related CI/PS application or PMCF/PMPF notification. The drop-down list only displays forms owned by the current Sponsor.

CI/PS - one-country app	lication -	Clear
* EU SIN of related CI/PS		
CI-EU-2023-022152	andatory field	
CI-EU-2023-022152	d in parallel with an applica	ation for a clinic
* Is this a combined investigation/study testing purpose) and/or is it an investigation/study testi Yes No	two different products (i.e. an MD and an IVD, which ing a combined product (MD + IVD)?	ו in combination reach an intended
EUDAMED Ref No : CI-LV-2023-022152-1 EU	SIN (European Single Identification Number) :	I-EU-2023-022152 / Change

You can only link forms that have been created by your Sponsor actor. You cannot link draft forms.

- 4. Reply Yes or No to the question *Is the application submitted in parallel with an application for a clinical trial on medicinal products?*
- 5. If you reply Yes, you must provide EU Clinical Trial number.

Is the application submitted in parallel with an application for a clinical trial on medicinal products?
○ No
*EU Clinical Trial number
Add

6. To add other EU clinical trial number click Add.

Coordinating investigator

Insert the details of the coordinating investigator.

Coordinating investigator	
First name 🔒	Last name 🔒
Street 🔒	Street number 🔒
Postal code 🔒	City name 🔒
Country	Telephone number 🔒
Select a value	- I I I I I I I I I I I I I I I I I I I
Email 🔒	

3.1.6 Common documents and statements

- 1. Click **Common documents and statements** on the left menu.
- 2. To upload a document, click *Browse* and then select it from your computer.

*	nvestigator's brochure 🔒		
	Choose file	Browse	



3. You can add several documents for each topic. To do it, click Add document.

* Investigator's brochure 🔒	
Brochure_inv.pdf	Delete
Add document	



NOTE

The investigator's brochure is not mandatory if you are submitting a PMCF/PMPF notification.



NOTE

Click **delete** to replace the uploaded file with another one, or **remove** to eliminate the document instance (only available when there are at least two file instances).

- 4. The following documents will not be publicly available:
 - Investigator's brochure
 - Clinical investigation/Performance study plan (for CI/PS application only)
 - PMCF/PMPF investigation plan (for PMCF/PMPF only)
 - Technical documentation as risk analysis, test report, etc.
 - Overall synopsis of clinical investigation/performance study (Referenced in MDR Chapter II 3.1.5 in annex XV/IVDR Part A 2.3.2 (g) in annex XIII)
 - Statement of conformity
- 5. The following documents will be **public**:
 - Scientific opinion/Expert panel views
 - Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/personal information
- 6. The following documents will be **public only once the End report and summary** of the CI/PS or PMCF/PMPF are published.
 - Clinical investigation/Performance study plan
 - PMCF/PMPF investigation plan
- 7. For these documents, you will be asked to **confirm that they do not contain private information**. To do it, you must tick the box.

Thoose file	Browse
-------------	--------

8. If the document has private information, do not tick the box. Instead, you must **upload a redacted version** of the document to make it public.

Choose file	Browse
☐ This document is foreseen to be public.	
Please confirm that the file does not contain any private	information
If required, please upload a redacted version of the doct	ument to make public below.
Add public version	

- 9. On the clinical/performance evaluation plan, reply Yes or No to the question Will the relevant document(s) be uploaded?
- 10. **If you reply Yes**, you will be asked to provide the Clinical/Performance evaluation plan.

* Will the relevant document(s) be uploaded?	
Choose file	Browse

If you reply No, you will be asked to provide the *Clinical/Performance evaluation plan reference number*.



11. At the end of the screen, **acknowledge the Ethics Committee statement**, i.e., the Competent Authority may contact the Ethics Committee that is assessing or has assessed the application.

Ethics Committee	_ I understand that the Competent Authority may contact the Ethics Committee that is assessing or has assessed
statement 🔒	the application

3.1.7 Investigational/Study device(s)

Click Investigational/study device(s) in the left menu.

Click + Investigational/Study device(s) to expand the section.

		1/01		1	/ \
Investio	ation	al/Sti	Idv c	10VICA	(0)
	auon	anou	uuv (131

+ Investigational/Study device

Add



NOTE

For each Investigational/Study device(s), the system generates a new sub-section under the *Language-specific investigational/study device(s) information* header of the *National Information* section with the same identifier as the *Investigational/Study device(s)*.

Previous investigation/study?

Reply Yes or No to the question Has this device been previously investigated/studied in a CI/PS or PMCF/PMPF within the EU?

If you reply Yes, a new field will appear for you to provide the relevant reference number(s) (such as SIN, CIV-ID, other reference(s)) of the previous CI/PS(s) or PMCF/PMPF(s).

Yes	Clear
ease provide the relevant r	ference number(s) (such as SIN, CIV-ID, other reference(s)) of the previous CI/PS(s) or
ease provide the relevant r MCF/PMPF(s)	eference number(s) (such as SIN, CIV-ID, other reference(s)) of the previous CI/PS(s) or

Device information

- 1. Reply Yes or No to the question Do any of the following device types apply?
- 2. If you reply Yes, select the Device type(s):

* Device type Check all Uncheck all
Implantable
Active device
Measuring function
Reusable surgical instrument
Intended to administer or remove medicinal substance
System
Non-medical purpose
Sterile
Software

- 3. Reply to the question *Is the device CE marked?*
- 4. Based on the response, certain fields will become available (and mandatory) or not:

Is the device CE marked?	Yes	Is the device registered in EUDAMED?	Yes	Provide: Unique Device Identification (UDI-DI / EUDAMED ID)
				Confirm that the CE-marked device will be used outside the scope of its CE mark by ticking the box
			No	Provide:
				UDI-DI - not registered in EUDAMED
				Issuing entity
				Confirm that the CE-marked device will be used outside the scope of its CE mark by ticking the box
	No	No further action		

5. Reply Yes or No to the question Is a Notified Body involved?

is a mandatory field	
Yes	
No mber	
liber	

6. If you reply Yes, you must select from the drop-down list the Notified Body number.

Yes	- Clear	
Notified Body numb	er	
1639 - SGS Belgium N	/	
0546 - CERTIQUALITY	S.r.l.	
0050 - National Standar	ds Authority of Ireland (NSAI)	
0537 - Eurofins Expert	Services Oy	
0459 - GMED SAS		
1912 - DAREII Services	B.V.	
0197 - TÜV Rheinland l	.GA Products GmbH	
0344 - DEKRA Certifica	tion B.V.	
2862 - Intertek Medical	Notified Body AB	
1026 TUV Deciplored	talia SDI	

7. Once you select the Notified Body number, its data will be displayed.

Confirmation is a mandate	ry field	
* Is a Notified Body involved?		
Yes	- Clear	
Notified Body number		
Actor ID/SRN:	0044	Change
	0011	p <u>onungo</u>
Organisation name:	TÜV NORD CERT GmbH	
Address:	Langemarckstraße 20, 45141 Essen 45141 Essen Germany	

8. To change the Notified Body number click Change at the top right of the grey box.

Confirmation is a mandat	ory field	
* Is a Notified Body involved?		
Yes	- Clear	
Notified Pedy number		
Notified Body number		
Actor ID/SRN:	0044	<u> </u>
Organisation name:	TÜV NORD CERT GmbH	
Address:	Langemarckstraße 20, 45141 Essen 45141 Essen Germany	

Investigational/Study device details

- 1. In this section provide the details of the device:
 - Device ID
 - Device name
 - Device trade name
 - EMDN nomenclature code
 - Nomenclature text/ Description of the device and its intended use retrieved automatically based on the code selected
 - Risk class (choose from the list only one option is possible)
 - Device description
 - Intended (clinical) purpose


Device ID (like model number/	/version)
dfdf	
*Device name	
Device trade name	
* EMDN nomenclature code	
Please select	-
* Nomenclature text/ Descriptio	on of the device and its intended use
	0
Nomenclature text/ Description of the dev	vice and its intended use is a mandatory field
Risk Class	
O CLASS III	
O CLASS IIb	
○ CLASS IIa	
0 02 100 114	
CLASS I	
 CLASS I *Device description 	
 CLASS I *Device description 	•
CLASS I *Device description	()
 CLASS I *Device description Device description is a mandatory field *Intended (clinical) purpose 	0
 CLASS I *Device description Device description is a mandatory field *Intended (clinical) purpose 	0

2. Reply Yes or No to the question Does the device contain or incorporate medicinal substance(s)?

Voc	ncorporate medicinal substance(s)? is a mandatory field
165	hame(s)
No	

3. If you reply Yes, you must provide the name of the medicinal substance.

Does the device contain or in	ncorporate medicinal substance(s)?
Yes	- Clear
Medicinal substance name(s))
	0
ledicinal substance name(s) is a mand	atory field

4. To add more medicinal substances click Add.

*Medicinal substance name(s)		
	0	
Medicinal substance name(s) is a mandatory field		
Add		

5. Reply Yes or *No* to the question *Does the device include human blood or plasma derivatives?*



6. Reply Yes or No to the question Does the device incorporate, as an integral part, or is it manufactured using non-viable biological substances?

If you reply Yes, you must complete the relevant value(s) for the field *Please select* the appropriate value(s).

You can select several options.

* Does the device incorporate	e, as an integral part, or is	it manufactured using non-viable biological substances?	
Yes	✓ C	Xear	
* Please select the appropriat	e value(s)		
Please select the appropriate value(s) i	s a mandatory field		
Check all Uncheck all			
Non-viable tissues of human	n origin or their derivatives w	vith an ancillary action	
Non-viable cells of human o	rigin or their derivatives with	n an ancillary action	
Non-viable tissues of anima	origin or their derivatives w	vith an ancillary action	
Non-viable cells of animal or	rigin or their derivatives with	an ancillary action	
Non-viable biological substa	nce other than those referre	ed to in the previous points	

7. Reply Yes or No to the question Has the device been subject to scientific views/an opinion from an Expert Panel and/or EURL?



Manufacturer of the investigational/study device and Manufacturer information

Reply Yes or No to the question Is the manufacturer the same as the sponsor?

	e as the sponsor? is a mandatory field	
Yes	registered in EUDAMED?	
No	- Clear	

- is not CE marked or
- is CE marked but it is not registered in EUDAMED,

you need to reply reply Yes or No to the question Is the manufacturer registered in EUDAMED?



If you reply Yes, you will be asked to select from the dropdown list the Actor ID/SRN of the manufacturer.





You will also have to indicate if the manufacturer has an authorised representative. If you reply *Yes*, you must select from the dropdown list its Actor ID/SRN as well.

* Does the manufacture	r have an Authorised represe	ntative?
Yes	•	Clear
Actor ID/SRN]
BE-AR-000000002	ld]
BE-AR-00000003		
BE-AR-000000005		
BE-AR-00000006		
BE-AR-00000082		
BE-AR-000000121		
BE-AR-000000142		

If the **manufacturer is not registered** in EUDAMED you must provide its details. The details of the contact person will not be made publicly available.

lanufacturer information	
Manufacturer	
*Organisation name	
*Street number	*Postal code
*City name	* Country
*Telephone number	*Email
Contact person of the manufacturer	
*First name 🔒	*Last name 🔒
*Telephone number 🔒	*Email 🔒

Below you can find a **summary table** where you can check the data you need to provide depending on certain conditions.

Do I need to provide the following data?	The device is not CE marked - CI/PS only, option not applicable for PMCF/PMPF	The device is CE marked but is not registered in EUDAMED	The device is regis	tered in EUDAMED
			CI/PS	PMCF/PMPF
UDI-DI/EUDAMED ID			Yes	Yes
UDI-DI - not registered in EUDAMED		Yes		
Issuing entity		Yes		
I confirm that the CE-marked device will be used outside the scope of its CE mark		Yes, for CI/PS only	Yes	
I confirm that the CE-marked device will be used within the scope of its CE mark		Yes, for PMCF/PMPF only		Yes
Investigational/Study device	details			
Device ID (like Model number / Version)	Yes	Yes	Yes	Yes
Device name	Yes	Yes	Only if different from registered device data	
Device trade name	Yes	Yes	Only if different from registered device data	
EMDN nomenclature code and nomenclature text	Yes	Yes	Select the EMDN code of the registered device that applies to the current CI/PS	Select the EMDN code of the registered device that applies to the current PMCF/PMPF
Risk Class	Yes	Yes	Yes	
Device description	Yes	Yes	Yes	Yes

Do I need to provide the following data?	The device is not CE marked - CI/PS only, option not applicable for PMCF/PMPF	The device is CE marked but is not registered in EUDAMED	The device is regis	tered in EUDAMED
Intended (clinical) purpose	Yes	Yes	Yes	Yes
Does the device contain or incorporate medicinal substance(s)?	Yes	Yes		
Does the device include human blood or plasma derivatives?	Yes	Yes	Yes	
Does the device incorporate, as an integral part, or is it manufactured using non- viable biological substances?	Yes	Yes	Yes	Yes
Has the device been subject to scientific views/an opinion from an Expert Panel and/or EURL?	Yes	Yes	Yes	Yes
Manufacturer of the investiga	tional/study device			
Is the manufacturer the same as the sponsor?	Yes	Yes	Yes	Yes
Is the manufacturer registered in EUDAMED	Yes	Yes		

You need to provide the authorised representative details only if the manufacturer is registered in EUDAMED **and** the country of the manufacturer is non-EU.

3.1.8 Comparator

- 1. Click **Comparator** from the left menu.
- 2. Indicate if there is at least one Comparator that is a medical device and if there is at least one Comparator other than a medical device, by selecting *Yes* or *No*.

Please select	*
there at least one comparator of	her than a medi
there at least one comparator of	her than a medi
there at least one comparator of	her than a med

3. If you reply Yes to the first question, a new sub-section will appear for you to choose the type of Comparator device, which depends on the legislation selected in the first step.

Comparator
- Comparator
*Kind of comparator
andatory field Medical device

4. If you reply Yes to the second question, the system will display a list for you to choose the type of Comparator. You can select more than one option.

Yes	•	Clear
Type of comparator(s) oth ype of comparator(s) other than	ner than device device is a mandatory field	
Therapy		
Placebo		

- 5. The following Comparators require further information:
 - · Medical device
 - IVD medical device
 - IVD medical device according to Art 5(5) of the IVDR
- 6. To fill in the information of the above Comparators, follow the explanation presented in the chapter *Investigational/Study device(s)*.



NOTE

For each Comparator device, the system generates a new sub-section under the *Language-specific Comparator device(s) information* header of the *National Information* section with the same identifier as the Comparator.

7. Below you can find a summary table where you can check the data you need to provide depending on certain conditions.

Do I need to provide the following data?	The medical device Comparator is not CE marked - CI/PS only, option not applicable for PMCF/ PMPF	The medical device Comparator is CE marked but is not registered in EUDAMED	The medical devi registered i	ce Comparator is n EUDAMED
			CI/PS	PMCF/PMPF
UDI-DI / EUDAMED ID			Yes	Yes
UDI-DI - not registered in EUDAMED		Yes		
Issuing entity		Yes		
I confirm that the CE- marked device will be used outside the scope of its CE mark		Yes (PMCF/PMPF)		Yes
Will the CE-marked Comparator medical device be used in the clinical investigation/performance study within the scope of its CE mark?		Yes (CI/PS)	Yes	
Investigational/Study device	e details			
Device ID (like Model number / Version)	Yes	Yes		
Device name	Yes	Yes		
Device trade name	Yes	Yes		
EMDN nomenclature code and nomenclature text				
Risk Class	Yes	Yes		
Device description	Yes	Yes	Yes	Yes
Intended (clinical) purpose	Yes	Yes	Yes	Yes
Does the device contain or incorporate medicinal substance(s)?	Yes	Yes		
Does the device include human blood or plasma derivatives?	Yes	Yes		
Does the device incorporate, as an integral part, or is it manufactured using non-viable biological substances?	Yes	Yes		
Has the device been subject to scientific views/an opinion from an Expert Panel and/or EURL?	Yes	Yes		
Manufacturer of the investig	gational/study device			
Is the manufacturer the same as the sponsor?	Yes	Yes		
Is the manufacturer registered in EUDAMED	Yes	Yes		
Manufacturer Actor ID / SRN or Manufacturer details	Yes	Yes		

3.1.9 National information

Click National Information (country name) in the left menu.

National clinical investigation/performance study information

IMPORTANT

If you are submitting an application for additional country(ies) or a pre-existing application/notification for which an EU SIN exists, this section is not pre-populated and you need to fill in the national information for each additional country(ies).

1. At the top of the screen, every national information section (one per country, in case of an application for coordinated assessment), you can see the national single identification number (SIN).

National Single Identification Number CI-LV-2023-022152

2. Indicate the expected number of subjects for the country.

3. Reply Yes or No to the question Is the sponsor commercial?

*Is the sponsor	commercial?	
Yes	nt Authority 🔒	
No	· · · · · · · · ·	•

- 4. Provide the details of the Local Competent Authority:
 - Identification of the Local Competent Authority (the system will give you the relevant results) this value determines the Competent Authority that will validate and authorise (when relevant) the submission
 - · Responsible Ethics Committee for the entire country
 - Responsible Ethics Committee opinion (define if is Positive, Negative or Unknown).

Please select			-	
Responsible Eti	nics Committe	e for the entire	country A	
	lies commune			

National investigational/study site(s)

- 1. Provide the details of the site:
 - Site number
 - · Site name
 - Site address

Site number		
*Site name		
- Site address		
*0//		
*Street	~Street number	
*Postal code	*City name	

2. To add more sites, click Add.

National investigational/study site(s)	
+ Site	
Add	

- 3. Provide the details of the investigator:
 - Investigator role
 - · Clinical department
 - · Investigator details (first name, last name, telephone number and email)

Investigator information	
- Investigator information	
* Investigator role	
 Other (sub-)investigator 	
* Clinical department 🔒	
Investigator details	
* First name 🔒	* Last name 🔒
* leiepnone number	
Add	

4. To add more investigators you need to have the *Site* section expanded. Then click *Add*.

- Investigator details		
* First name 🔒	* Last name 🔒	
* Telephone number 🔒	* Email 🔒	
* Clinical department		
Add		

- 5. Provide the Documents related to the investigational/study site:
 - CV of the investigator
 - All information related to the suitability of center including signature
 - All information related to the suitability of center excluding signature *

· Other national requirements

of the investigators 🔒	
Choose file	Browse
Add document	
information related to the suitability of center including signature $igoplus$	
Choose file	Browse
Add document	
Il information related to the suitability of center excluding signature	
Choose file	Browse
 This document is foreseen to be public. Please confirm that the file does not contain any private information 	
 This document is foreseen to be public. Please confirm that the file does not contain any private information If required, please upload a redacted version of the document to make p 	ublic below.
 This document is foreseen to be public. Please confirm that the file does not contain any private information If required, please upload a redacted version of the document to make p Add public version 	ublic below.
 This document is foreseen to be public. Please confirm that the file does not contain any private information If required, please upload a redacted version of the document to make p Add public version 	ublic below.
 This document is foreseen to be public. Please confirm that the file does not contain any private information If required, please upload a redacted version of the document to make p Add public version Add document her national requirements A	ublic below.

* For this document **you must acknowledge that it does not contain private information**, as it is expected to be public. To do it, tick the box.

6. Select the language(s) in which you will provide the national information from the dropdown list.

of the application.
al information

7. You can add more languages by clicking Add.

*Select the language(s) in which you wi	ill provide the	nation
German	-	Clear
Add		

8. As soon as a language is defined in the field above, the system will generate the relevant number of dedicated *National language-specific information* sections:

* Select the language(s) in which you will provide	the national information	
French	▼ Clear	Remove
German	- Clear	Remove
Add		
National language-specific info	ormation	
+ National language-specific information		
+ National language-specific information		

National language-specific information

- 1. Provide the following information of the CI/PS in the relevant national language:
 - Full title
 - Title for lay people
 - Description for Design methodology Other only if this value was selected for Design methodology previously
 - Description for Type of subjects Other only if this value was selected for Type of subjects previously
 - Primary objective
 - · Secondary objective
 - Other objective(s)
 - Primary endpoint
 - · Secondary endpoint
 - Other endpoint(s)
 - Overall synopsis
 - Inclusion criteria
 - Exclusion criteria

2. National language-specific Investigational/study (and Comparator) device(s) information sections:

National language-specific investigational/study device(s) information

- + Device [12121212121]
- + Device [Device id that I entered]
- + Device [this is the UDI-DI that is not registered in EUDAMED]

National language-specific comparator device(s) information

- + Device [12312121]
- + Device [this is the device id]
- 3. As soon as the sections *Investigational/Study devices* and *Comparator* are filled in, the system will create the correct number of sub-sections, if any.
- 4. For each sub-section (*Investigational/Study device(s)* and *Comparator*), provide the following information in the relevant language:
 - Device name not applicable to PMCF/PMPF notification or to the Comparator section
 - Device trade name not applicable to PMCF/PMPF notification or to the Comparator section
 - Device description
 - Intended (clinical) purpose
- 5. Provide the following documents in the national language:
 - Instruction for use
 - Informed consent/Patient information leaflet *
 - Ethics Committee opinion *
 - Proof of insurance
 - · Other national requirements

* For these documents **you must acknowledge that they do not contain private information**, as they are expected to be public. To do it, tick the box.

choose file	Browse
-------------	--------

6. If you are uploading a document that is expected to be public and it contains private information, you must **upload a redacted version**. To do it, click *Add public version*.

Choose file	Browse
This document is foreseen to be public.	
Please confirm that the file does not contain an	y private information
If required, please upload a redacted version of	f the document to make public belov

4 Submit an application/ notification

1. Once you have completed the application, click **Submit** at the top right of the screen.

CURRENT ACTOR: Sponsor, IT-SP-000007947, Sponsor C	organisation - Italy [Italy]
	Submit

2. A pop-up window will appear for you to complete your action.



I/PS application that was allowed	to start before EUDAMED CI/F	PS was available: Are you sure you wa
submit this (version of the) form?		
Draft With Submitter	Draft With Submitter	Under validation With Competent Authority for validatio
Comments		
Comments		
Comments Attachment (PDF)		

3. If you are not yet ready to submit the application, click **Close**. The record will remain in *Draft* state.

To confirm the submission, click **Complete action**.

PS application that was allowed t	to start before EUDAMED CI/F	2S was available: Are you sure you wa
submit this (version of the) form?	•	
Draft With Submitter	Draft With Submitter	Under validation With Competent Authority for validation
Comments		
Comments		
Comments Attachment (PDF)		
Comments		



WARNING

If there is any field that is not completed correctly, the system will display the blocking error(s) at the right-hand side at the top of the screen.

CURRENT ACTOR: Sponsor, IT-SP-000007947, Sponsor Organisation - Italy [Italy]		No "Ethics Committee statement" provided in section Ethics Committee statement	×
		Go to validation error	
		No remaining validation errors	×
	Submit	Clear all validation messages	

1. Click on *Go to validation error* to be guided to the appropriate section and field that generates the error so that you can directly correct the information.

Add document			No "Ethics Committee statement" provided in section Ethics Committee statement	×
Clinical/Porform	ance evaluation plan			
Cirrical/Fertorina			No remaining validation errors	×
	ti(s) be uploaded? 💼 🐨		Clear all validation messages	
* Clinical/Performance eva	luation plan 🔒			
test.pdf	Delete			
Add document				
Ethics Committe	ee statement			
* Ethics Committee statement	I understand that the Competent Authority may contact the Ethics Committee that is asses the application Ethics Committee statement is a mandatory field	sing or has assessed		

- 2. Click on *Clear all validation messages* to hide the messages.
- If several error messages apply, the system will only show the first 3 error messages in an individual orange box followed by a blue box that tells you how many additional errors remain.
 These additional errors will be displayed gradually once the first 3 errors have

I hese additional errors will be displayed gradually once the first 3 errors have been corrected.



- 4. If there are no blocking errors for submission, the state of your application will change to:
 - Under validation for the CI/PS application one country
 - Notified for the PMCF/PMPF notification
 - Awaiting coordinator CI/PS single application coordinated assessment

You can check it on the Search and Manage page.

<u>CI-BE-2024-002528-1</u>	CI/PS application - one country	IT-SP-000007947		2024-09-06	Under validation	

5. Once you have submitted your application, you can check the workflow actions and comments on the *Report history overview* section of the application. The workflow section displays the deadline for the competent authority to validate the application or to acknowledge the notification. As long as it is not done, the sponsor cannot perform any further actions.

	0	Validation process	
06/09/2024 16:28 Ø Version: 1	0	Under validation Submission date : 06/09/2024 16:28	

6. The submission will trigger a notification to the concerned Competent Authority (CA) and the clock starts.

If you have submitted a PMCF/PMPF notification, the competent authority is notified and should acknowledge it within the deadline. However, if the competent authority does not acknowledge receipt of the PMCF/PMPF notification within the deadline, the PMCF/PMPF is allowed to start.

NOTE If you are submit application will ge	ting a CI/PS single et the state <i>Awaiting</i>	application - coordinated asse	ssment the	
CI/PS single AT-SP-000008 application - coordinated assessment	61 PCTA240830090927104 (PVTA240830090927330)	TitleForLayPeople,TFLPTA240830090928380,TitleForLayPeople	2024-08-30	Awaiti coord
The Report histo	ry overview screen	will look as follows:		
The Report histo	ry overview screen	will look as follows:		
The <i>Report histo</i> 30/08/2024 🕑 11:15	ry overview screen	will look as follows:		
The Report histo 30/08/2024 11:15 ≷ Version: 1	ry overview screen Awaiting coordinato Submission date : 30/08	will look as follows: r 8/2024 11:15		
The Report histo 30/08/2024 11:15 Sterion: 1	ry overview screen Awaiting coordinato Submission date : 30/08 Deadline : 30/08/2024	will look as follows: r 8/2024 11:15		
The Report histo 30/08/2024 11:15 € Version: 1	ry overview screen Awaiting coordinato Submission date : 30/08 Deadline : 30/08/2024 DKUMAR-Submit CI/PS	will look as follows: r 8/2024 11:15 8 - Application Form		
The Report histo 30/08/2024 11:15 ♥ Version: 1	ry overview screen Awaiting coordinato Submission date : 30/08 Deadline : 30/08/2024 DKUMAR-Submit CI/PS	will look as follows: r 8/2024 11:15 8 - Application Form		



NOTE

You will receive a notification every time there is a change to your application via EUDAMED platform³. There are two types of notifications: *Action* and *Information*.

1. Go to the top of the screen and click *Notifications*:



2. Define the parameters to refine your search and then click on Search.



3. The system will present you the relevant results.



³Once the module goes to production, the user will also receive the notifications via email.

5 Search and manage application / notification

Click Manage CI/PS application and PMCF/PMPF notification.

Welcome to EUDAM	ED			
MDR EUDAMED is the IT system developed by the European Commission to implement Regulation (EU) 2017/745 C on medical devices and Regulation (EU) 2017/746 C on in vitro diagnosis medical devices.			Release note 🗎 2024-07-25 Release note!	
MDR EUDAMED is structured around 6 interco	nnected modules and a public site.			
Tasks				
According to your profile per module, consult, v	erify and/or manage your own and related	i data (man	aged by your actor)	
	User management		UDI-DIs/Device	CI/PS
	Assess user access requests	🞺 3	Manage your NRDs	Manage CI/PS application and PMCF/PMPF notification
	Manage your users			Register CI/PS application or PMCF/PMPF
Manage your actor data				
Manage your email notifications				

You will arrive to the Search and manage application / notification CI/PS items page.

Search and Manage	CI/PS items	Create CI/PS Form +
Search		
Search criteria	Value	
Please select		
Add		
Search		
My CI/PS Items		0 ITEMS LISTED

5.1 Search CI/PS items

On the *Search and manage* page, depending on your user rights, you can see the records of your Sponsor actor in all states.

To **search a report**, use the search tool and follow these steps:

1. Go to the Search criteria field and select the relevant criterion from the drop-down list.

Search criteria		
Please select		
Form Type		
Country for this one- application/notification	country on	
State		
Deadline (date)		
Sponsor Actor ID/SR	N	
Authorised Represen	ntative Actor ID/SRN	
Арр̂пса́циіт т.) Ъ	гопп туре 🗸	oponsor A

2. Enter the value matching your search criteria, i.e., if you chose *State*, the value could be *Draft, Under validation*, etc.

Search	
Search criteria	Value
State	Draft



NOTE

In the case where the search criterion refers to a pre-defined list of values, as soon as you start typing in the field *Value*, the system will present the relevant results.

3. Add other relevant search criteria if needed. To do it, click Add.

Search		
Search criteria		Value
State	×	Draft
Add		

Search and Manag	ge CI/PS iter	ns		
Search				
Search criteria		Value		
Form Type	×	CI/PS single application - coordinated assessment	×	Remo
Form Type	×	CI/PS application - one country	×	Remo

4. Click **Search** and the system will display the relevant results.

State				Fil			
Add	ch			1			
h							
arch criteria		Value					
ate	3	Draft		×			
Search	Clear search						
Search y CI/PS Items owing 1 to 5 of 5 entri	Clear search				show: 20 ♥	ENTRIES PER	PAGE
Search IV CI/PS Items nowing 1 to 5 of 5 entri poplication ID \$	Clear search es Form Type ≎	Sponsor Actor ID/SRN ≑	Cl/PS plan code (Cl/PS plan version) ≑	Title for lay people ≑	show. 20 ⊽ Last update date ≑	entries per State ≑	Action
Search IV CI/PS Items Inving 1 to 5 of 5 entri Diplication ID \$ -LV-2023-022152-R2	Clear search es Ci/PS application - one country	Sponsor Actor ID/SRN ¢ PT-SP-000000925	CVPS plan code (CVPS plan version) ¢ Prandska te u canacid 3 c°nordu os taul demoir 1 \}	Title for lay people ≑ Franciska test demo 4.3,Franciska test demo 4.3	SHOW: 20 v Last update date \$	ENTRIES PER State \$ Draft	Action
Search Iy CI/PS Items nowing 1 to 5 of 5 entri opplication ID \$ -IV-2023-022152-R2 -IT-2023-022355-1	Clear search es Form Type CI/PS application - one country CI/PS application - one country	Sponsor Actor ID/SRN ≑ PT-SP-000000925 PT-SP-000000925	CI/PS plan code (CI/PS plan version) ¢ Prancisky fast canso d 3 (Tranciska fast demok 1 \}	Title for lay people ≎ Franciska test demo 4.3,Franciska test demo 4.3	SHOW: 29 V	ENTRIES PER State \$ Draft Draft	Action Delete
Search Iy CI/PS Items nowing 1 to 5 of 5 entri opplication ID \$ -LV-2023-022152-R2 -IT-2023-022355-1 -IS-2023-022152-3	Clear search Form Type Cl/PS application - one country Cl/PS application - one country Cl/PS application - one country	Sponsor Actor ID/SRN + PT-SP-000000925 PT-SP-000000925 PT-SP-000000925	CI/PS plan code (CI/PS plan version) € Pranciska test denne d 3 (Tranciska test denne d 3) Franciska test denne d 3) Franciska test denne d 4)	Title for lay people ≎ Franciska test demo 4.3,Franciska test demo 4.3 Franciska test demo 4.3	SHOW 20 V	ENTRIES PER State ÷ Draft Draft Draft	Action Delete Delete
Search ly CI/PS Items www.mg 1 to 5 of 5 entri opplication ID \$ -LV-2023-022152-R2 -LT-2023-022152-1 -LS-2023-022152-3 -EU-2023-022152-2	Clear search Form Type ≎ CI/PS application - one country CI/PS application - one country CI/PS application - one country CI/PS single application - coordinated assessment	Sponsor Actor ID/SRN \$ PT-SP-000000925 PT-SP-000000925 PT-SP-000000925 PT-SP-000000925 PT-SP-000000925	CI/PS plan code (CI/PS plan version) ¢ Pranciska test canoc 4.2 cfoordb optavil demon 1.9 e tanasch tost canoc 1.9 e tanasch tost canoc 1.9 e tanasch tost canoc 1.9 e tanasch tost canoc 1.9	Title for lay people \$ Franciska test demo 4.3, Franciska test demo 4.3 Franciska test demo 4.3 Franciska test demo 4.3	SHOW: 20 V	ENTRIES PER State \$ Draft Draft Draft Draft	Action Delete Delete Delete

If you are searching using the criterion *Deadline (date)*, keep in mind that the system will not present applications in state *Authorised*, as no deadlines apply in this case.

The results are sorted by default by date (closest deadline at the top of the search results list). Nonetheless, you can organise the results using the other columns available. To do it, use the arrows next to the title of each column.

arch							
Search criteria		Value					
State		X Under valida	tion	×			
Add							
Search	Clear search						
My CI/PS Items							
Showing 1 to 16 of 16 er	ntries				SHOW: 20	0 🗸 ENTRIES PE	R PAGE
-							
Application ID ≑	Form Type ≑	Sponsor Actor ID/SRN 🖨	CI/PS plan code (CI/PS plan version <mark>€</mark>	Title for lay people	Last update dat <mark>e</mark> 🗢	State ≑	Actio
CI-BE-2023-022253-1	CI/PS application - one country	AT-SP-00000861	PlanCode (planVersion)	titleForLayPeople,TitleForLayPeople	2023-11-30	Under validation	
CI-BE-2023-022170-1	CI/PS application - one country	AT-SP-00000861	PlanCode (planVersion)	titleForLayPeople,TitleForLayPeople	2023-11-30	Under validation	
CI-BE-2023-022157-1	CI/PS application - one country	BE-SP-000001041	CIPS-30.11.2023-Test2 (CIPS-30.11.2023-Vers2)	Test1923*, Test1923*	2023-11-30	Under validation	
CL RE 2022 022240 4	CI/DS application	AT CD 00000084	BlanCode (plan)(arcian)	TitleEarl avReeple titleEarl avReeple	2022 42 04	Under	

At the top of the list with the search results, select how many results you want to show per page:

My CI/PS Items					
Showing 1 to 16 of 16 ent	tries				SHOW: 20 V ENTRIES PER PAGE
Application ID \$	Form Type \$	Sponsor Actor ID/SRN \$	CI/PS plan code (CI/PS plan version) ≎	Title for lay people \$	Last update date 🗢 State 🗢 Action

playground

6 Withdraw an application



NOTE

You can withdraw an application/notification at any stage before the CI/PS or PMCF/ PMPF starts.

To withdraw an application/notification follow these steps:

- 1. Search for the application/notification on the Search and Manage CI/PS items page.
- 2. Open the application by clicking on the application ID.

My CI/PS Items							
Showing 1 to 1 of 1 entri	Showing 1 to 1 of 1 entries SHOW: 20 - ENTRIES PER PAGE						
Application ID 🗢	Form Type ≑	Sponsor Actor ID/SRN \$	CI/PS plan code (CI/PS plan version) ≑	Title for lay people ≎	Last update date ≑	State ≑	Action
CI-LV-2023-022152-R1	CI/PS application - one country	PT-SP-000000925	Franciska fest demo 4.3 (Franciska kest domo 4.3)	Franciska test demo 4.3,Franciska test demo 4.3	2023-12-06	Validated (may start)	<u>Delete</u>

3. Click **Withdraw** at the top right of the page.



4. A pop-up message will appear for you to complete your action.

e you sure you want to withdraw the I appear as 'Withdrawn' and you wil	e application/notification? If you Il no longer be able to update it.	confirm, the applicatio	n/notification
Under validation	Authorised	Withdray	wn
Vith Competent Authority for validation	The CI/PS is allowed to start	Application/notificatio	n is withdrawn
Withdraw application			
Withdraw application			

- 5. Use the *Justification* box to submit any relevant information related to your action.
- 6. Confirm your action by clicking **Complete action**.

e you sure you want to withdraw the I appear as 'Withdrawn' and you wi	e application/notification? If you Il no longer be able to update it.	confirm, the application/notification
⊘	—	•
Under validation	Authorised The CI/PS is allowed to start	Withdrawn Application/notification is withdrawn
Justification		
Justification Withdraw application		
Justification Withdraw application		

7. The state of the application/notification will change to *withdrawn*. You can check it on the *Search and manage* page or by going to the *Report history overview*.

CI/PS application -	AT-SP-00000861	2024-08-30	Withdrawn
one country			

playground

	1	Withdrawal	
18/09/2023 17:01 Seversion: 1	\checkmark	Withdrawn	
	1	Validation process	
06/09/2023 17:34 Sversion: 1	0	Under validation Submission date : 06/09/2023 17:34 Deadline : 16/09/2023	
		Test1923*	



7 Delete a draft application

To delete a draft application/notification follow these steps:

- 1. Go to the Search and manage CI/PS items page.
- 2. Search for the application/notification.
- 3. Click **Delete** on the Action column.

My CI/PS Items							
Showing 1 to 5 of 5 entries							
Application ID 🗢	Form Type ¢	Sponsor Actor ID/SRN \$	CI/PS plan code (CI/PS plan version) ≑	Title for lay people ≎	Last update date ≑	State 🖨	Action
CI-LV-2023-022152-R2	CI/PS application - one country	PT-SP-000000925	Franciska test densa 4.3 Franciska keytidente 4.2	Franciska test demo 4.3,Franciska test demo 4.3		Draft	<u>Delete</u>
<u>CI-IT-2023-022355-1</u>	CI/PS application - one country	PT-SP-000000925				Draft	<u>Delete</u>
CI-IS-2023-022152-3	CI/PS application - one	PT-SP-00000925	Longe for test time of S concerns to the factor of the	Franciska test demo 4.3		Draft	Delete

4. A pop-up message will appear for you to confirm your action. Click **Continue** to proceed. Otherwise, click **Cancel**.



5. The application/notification will be deleted and will disappear from the Search and manage CI/PS items page.



NOTE

Once you have deleted a draft application/notification, it is no longer possible to recover

8 Validation rejected - Edit and submit response to Competent Authority



NOTE You can follow the validation progress in the tab *Report history overview*.

If the **Competent Authority rejected your application** and has requested further information, you will receive a notification in the *Notifications Inbox*.

To check your notifications/actions, follow these steps:

• On the *Welcome to EUDAMED* page, go to the top and click on **Notifications**. Here you can find the relevant notification(s) relating to the status change of the application.

		👤 SP dev EU Logout
CURRENT AC	ror: Sponsor, PT-SP-000000925, Sponsor organis	sation - EU [Portuga
ent		
ro	See all the news	

On the Search and Manage CI/PS items page, the application will have the state *Validation rejected*. To open the application go to the Search and Manage CI/PS items page and click on the application ID.

Once you open it, at the top of the page, you will see the following options:

1. Create new version

Click on Create new version a. Create new version Withdraw NOTE In case the Competent Authority rejected a pre-existing application/ notification, the button to Withdraw is not available. A pop-up window will appear. Click Complete action. b. Dossier CI-BE-2024-002532-1 : Validation rejected After confirming, a new version of the application will be created in 'draft' status. Once you have updated the relevant information and/or document(s), you will be able to submit the changes to the Competent Authority. Under validation Validation rejected Validation rejected - update ongoing With Submitter With Competent Authority for validation Validation rejected - with deadline for

c. A **new version** of the CI/PS application will be created in state *draft*. You can edit it, by clicking **Edit** at the top of the page.

sponsor to react

Complete action

Close

Version : 2 [Draft] Last update : 🏥 2024-0	9-11		1	
< Back to list		Edit	Withdraw	Submit response to CA
Report Primary Details	Report Primary Details			

d. As soon as a new version is created, the application will change to *Validation rejected – update ongoing*.

	<u>. </u>	5					
08/12	08/12/2022 Validation		rejected - update ongoing				
08/12	/2022 2	Validation reje Deadline : 10/12 Please provide r	Validation rejected Deadline : 10/12/2022 Please provide more details on				
	— 1 Va	lidation process					
	NOTE The field CI/PS only field that y worldwide.	s <i>plan code</i> under rou cannot edit, as s Clin ₽ ₽	the <i>CI/PS identification</i> section is the s it is the unique identifier of the CI/PS ical investigation/Performance study plan				
0	IMPORTANT In the new versi icon and the fie	sion, the fields tha elds that have not	t have been edited will display a dark blue been edited will display a light blue icon.				
	CI/PS Descriptio CI/PS Descriptio Common docur	on - part 1 on - part 2 nents and statements	FDG - demo data November 2022 Set I/PS plan version FDG - demo data November 2022 - version 2 Set I/PS plan date 2022-11-01				
	Investigational/ Comparator National inform	Study device(s) ation	Clinical investigation/Performance				
	By clicking on history of that p	he dark blue icon particular field:	, you have an overview of the version				
Version history	×						
---	-------						
Version 2 2022-11-24 - 10:46:03							
CI/PS plan version							
Version 1 2022-11-24 - 07:30:31							
CI/PS plan version FDG - demo data November 2022							
	Close						

- e. Once you have updated the relevant information, submit the changes to the Competent Authority for validation by clicking **Submit response to CA**.
- f. A pop-up window will appear for you to provide the relevant comments. Once you are done, click **Complete action**.

the previous version?	•	
Validation rejected Validation rejected - with deadline for sponsor to react	Validation rejected - update ongoing With Submitter	Under review With Competent Authority for revie
* Comments		
* Comments		
* Comments Comments Attachment (PDF)		

g. The new version of the CI/PS application will now have the state Under review.

2. Withdraw





NOTE

For more information on how to withdraw an application see chapter *Withdraw an application*.

Once the response is submitted to the CA, the Sponsor can only withdraw the application. No further actions are available.

The Sponsor can follow every action taken by the CA by going to the tab *Report history overview*.

playground

9 Pending additional info – provide additional information

The CA can request additional information before the authorisation of the CI/PS application. If it happens, you will receive back the application as *Pending additional info*.



NOTE

There is no deadline for the Sponsor to react.

Once you open the application, at the top of the page, you have the option to:

- Create new version
- Withdraw

To perform the actions above, follow the same steps as described in *Validation rejected* - *Edit and submit response to Competent Authority* [67].

Once you have submitted the required information, the application will become Validated (pending authorisation).

Pending additional info – provide additional information

10 Submit normal update

You can submit a normal update to your application/notification when it has one of the following states:

- Notified (published), Acknowledged, Started or Temporarily halted (PMCF/PMPF)
- Validated (may start), Authorised, Started or Temporarily halted (CI/PS)

To do it, follow these steps:

1. Click Register normal update.

	Register normal update
eport Primary Details	
/DC application and country	

2. A pop-up window will appear. Click Complete action to proceed.

Dossier CI-BE-2024-0024	450-1 : Authorised	
After confirming, a new version of the the relevant information and/or docum Authority.	application will be created in 'dra nent(s), you will be able to submi Authorised The CI/PS is allowed to start	aft' status. Once you have updated t the changes to the Competent Authorised With Submitter
	[Complete action Close

3. A new version of the application will be created as *Draft*. At this stage, you will be able to *Edit* the relevant information in the application.

	Edit	Submit normal update
Report Primary Details		
Form Type CI/PS application - one country		



NOTE

You will not be able to change the value of the field *CI/PS plan code*. In the case of a coordinated assessment, the following fields cannot be edited either:

- the countries to which the coordinated assessment application has been submitted;
- the proposed coordinated Member State.
- 4. When all appropriate updates have been registered, click **Submit normal update**.

	Edit	Submit normal update
Report Primary Details		
Form Type CI/PS application - one country		

5. A pop-up window will appear for you to provide comments. Once you are done, click **Complete action**.



ossier CI-BE-2024-0024	450-1 : Authorised	
e vou sure vou want to submit this r	new version as a normal undat	te? The public information in this new
ersion will be published.		e? The public mornation in this new
O		
Authorised The CI/PS is allowed to start	Authorised With Submitter	Authorised The CI/PS is allowed to start
Comments		
Comments		
Comments Attachment (PDF)		
Comments Attachment (PDF) Choose file		Browse
Comments Attachment (PDF) Choose file		Browse



NOTE

Completing this action will generate a notification to the Competent Authority that a new version has been submitted.

Playground

11 Register start date

VIDEO: Register a CI/PS start date EUDAMED Video support

Once the application/notification is authorised to start, you can indicate the start date.

To do it:

- 1. Go to the top right corner of the page and click *Register start date*.
- 2. A pop-up window will appear. Fill in the start date and provide any relevant comments.



you confirm, the CI/PS or PMCF/F Notified The notification is submitted to the CA	PMPF will be visible as 'Started'. Acknowledged The notification is acknowledged	Started Started	
* Start date 2024-09-09 Comments			
* Responsible Ethics Committe	e opinion Clear		
Attachment (PDF) Choose file			Browse
		Complete action	Close
IMPORTANT If the <i>Responsible Eth</i> must have their positi	<i>hics Committee opinion</i> is <i>Ur</i> ve opinion before registering	<i>known</i> until this star the start date. Othe	ge, you erwise, the

- 3. Once all the mandatory fields are filled in, click *Complete action*.
- 4. The application/notification will now have the state *Started*.
- 5. Once the application/notification has started, you can *Create new version*.

78

EUDAMED user guide

Create new version		

12 Deadlines applying to the CI/PS application – one country

Key date/event	Process description	Deadline	Possibility of extension?	Period can be suspended?
Submission date	Sponsor submits CI/PS application			
Validation date	Time for validation decision by CA	10 days of submission date (FS-CI/PS-003.05)	Yes, + 5 days (LR-CI/PS-025)	
(in case of negative validation decision)	Time for sponsor to provide comments or complete application	10 days of negative validation decision	Yes, + 20 days	
Validation date	Time for CA to provide validation decision after additional comments or completion of application by sponsor	5 days of sponsor's feedback	Yes, + 5 days (LR-CI/PS-025)	
Authorisation date	Time for authorisation decision (assessment) by CA	45 days of validation date	Yes, + 20 days or + 50 days if Class IIb/C or Class III/D	Yes, while waiting for response sponsor: additional comment or complete application

Playground

13 Deadlines applying to the PMCF/PMPF notification

Key date/event	Process description	Deadline	Possibility of extension?
Submission date	Minimum period for sponsor to notify PMCF/PMPF investigation/study to the MSC	30 days before starting PMCF/ PMPF	No
	Maximum period for CA to acknowledge receipt of the notification (and to provide comments to sponsor)	30 days of submission date	No

Playground

14 Notifications triggered by the system

Identifier and subject of the EUDAMED notification	Recipient(s)	Triggered
CI/PS-001: Submission of CI/PS application - one country	CA selected in the National information section - Local Competent Authority field	At submission of the first version of the form
CI/PS-002: Submission of PMCF/PMPF notification - including sponsor validation information	CA selected in the National information section - Local Competent Authority field	At submission of the first version of the form
CI/PS-023: Submission of pre-existing CI/PS application - one country	CA selected in the National information section - Local Competent Authority field	At submission of the first version of the form for a CI/PS that was allowed to start before EUDAMED CI/PS is available
CI/PS-024: Submission of pre-existing PMCF/ PMPF notification	CA selected in the National information section - Local Competent Authority field	At submission of the first version of the form for a PMCF/ PMPF that was allowed to start before EUDAMED CI/PS is available
CI/PS-026: pre-existing CI/PS application or PMCF/PMPF notification: sponsor submitted response to rejection	CA selected in the National information section - Local Competent Authority field	At submission of a response by the sponsor to the rejection of a CI/PS or PMCF/PMPF that was allowed to start before EUDAMED CI/PS is available
CI/PS-042: CI/PS application - one country: outcome of validation process (generic)	Sponsor owner of the form and CA actor selected in the National information section - <i>Local Competent Authority</i> field	At submission of the validation decision by the CA (positive or negative)
CI/PS-025: registration of pre-existing CI/PS application or PMCF/PMPF notification was assessed by CA	Sponsor owner of the form	At submission of the CA assessment of a CI/PS or PMCF/ PMPF that was allowed to start before EUDAMED CI/PS is available
CI/PS-051: Submission for additional country(ies) - CI/PS one country	All CAs to whom another CI/PS application with the same EU SIN has already been submitted	At submission of a new application for additional countries for the same EU SIN
CI/PS-053: Submission for additional country - PMCF/PMPF notification	All CAs to whom another PMCF/PMPF notification with the same EU SIN has already been submitted	At submission of a new notification for additional countries for the same EU SIN
CI/PS-022: Sponsor submits normal update to CI/PS application or PMCF/PMPF notification	CA selected in the National information section - Local Competent Authority field	When the sponsor submits a new version of the application/notification that is not a substantial modification
CI/PS-005: CA extends deadline for validation of CI/PS application - one country	Sponsor owner of the form	When the CA extends the period for validation
CI/PS-006: CA extends deadline for sponsor in CI/PS application - one country	Sponsor owner of the form	When the CA extends the period for the sponsor to react to the initial rejection of the application
CI/PS-007: CI/PS application - one country: sponsor submitted response to rejection	CA selected in the National information section - Local Competent Authority field	When the sponsor submits a response to the initial rejection of the application
Cl/PS-009: The application is lapsed (no sponsor response before deadline)	Sponsor owner of the form and CA actor selected in the National information section - <i>Local Competent Authority</i> field	When the sponsor did not submit a response to the initial rejection of the application before the deadline expired
CI/PS-010: CI/PS application - one country: authorisation outcome	Sponsor owner of the form and CA actor selected in the National information section - Local Competent Authority field	At submission of the authorisation decision by the CA (positive or negative)
CI/PS-011: CI/PS application - one country: authorisation refused (corrective measure)	All CAs with CI/PS responsibilities and EC actor	When the CA refuses authorisation of a CI/PS application - one country. This is considered to be a corrective measure and is therefore communicated to all CAs and the EC.
CI/PS-012: Request additional information during authorisation - one country	Sponsor owner of the form and CA actor selected in the National information section - Local Competent Authority field	When the CA submits a request for additional information during the authorisation process
CI/PS-013: Provide additional information during authorisation - one country	CA selected in the National information section - Local Competent Authority field	When the sponsor submits a response to the request for additional information from the CA
CI/PS-014: CA extends deadline for authorisation of CI/PS application - one country	Sponsor owner of the form	When the CA extends the period for authorisation
CI/PS-015: PMCF/PMPF - no reaction from CA	Sponsor owner of the form	When the CA does not submit a response to the PMCF/ PMPF notification after 30 days
CI/PS-016: PMCF/PMPF is acknowledged by CA	Sponsor owner of the form	When the CA acknowledges receipt of the PMCF/PMPF notification
CI/PS-027: CI/PS application - one country is withdrawn by sponsor	All CAs with CI/PS responsibilities and EC actor	When the sponsor withdraws the CI/PS application

EUDAMED user guide

Identifier and subject of the EUDAMED notification	Recipient(s)	Triggered
CI/PS-029: PMCF/PMPF notification is withdrawn by sponsor	All CAs with CI/PS responsibilities and EC actor	When the sponsor withdraws the PMCF/PMPF notification
CI/PS-018: Sponsor defined (re)start date for a participating country	CA selected in the National information section - Local Competent Authority field	When the sponsor submitted the start date or the restart date of a CI/PS or PMCF/PMPF
CI/PS-008: Sponsor actor data ready for publication	Sponsor for which the actor data was 'validated' implicitly	When the CA positively validates a CI/PS application or acknowledges receipt of a PMCF/PMPF notification



